相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Infectious Diseases
Deborah Cromer et al.
Summary: By analyzing data on in-vitro neutralization and clinical protection, the study found that neutralizing activity against the ancestral SARS-CoV-2 is highly correlated with neutralization of variants of concern, and can still predict the vaccine's protection against these variants. Simulation results suggest that booster vaccination for previously infected individuals can provide higher levels of protection compared to primary vaccination. Although the protection may decrease within the first year after vaccination, the current vaccines can still offer robust protection in the medium term.
Article
Infectious Diseases
Wan Ni Chia et al.
Summary: The study investigated the dynamics of neutralising antibody response in patients who have recovered from COVID-19, finding great variations and suggesting that predicting immune longevity can only be accurately determined at the individual level. The findings emphasize the importance of public health and social measures in the ongoing pandemic outbreak response, and may have implications for the longevity of immunity after vaccination.
Article
Medical Laboratory Technology
Andrea Padoan et al.
Summary: This study compared neutralizing antibody (NAb) production after BNT162b2 vaccination using different detection methods, finding strong NAb production 28 days after the first dose of the vaccine, as well as differences in the correlation between NAb titers and circulating antibodies measured by different immunoassays.
CLINICA CHIMICA ACTA
(2021)
Article
Medicine, General & Internal
Mark W. Tenforde et al.
Summary: This study evaluated the association between mRNA COVID-19 vaccines and COVID-19 hospitalization, as well as disease progression to critical illness among hospitalized patients. The results showed that vaccination with mRNA COVID-19 vaccines significantly decreased the likelihood of COVID-19 hospitalization and disease progression to death or mechanical ventilation.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Einav G. Levin et al.
Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Johad Khoury et al.
Summary: The antibody levels decline rapidly one month after the second dose of the vaccine, with the average antibody level four months after vaccination being only 6% of the peak levels. During the study period, there were 4 breakthrough infections, all of which were mild or asymptomatic, with a sharp elevation in antibody levels seen after infection.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Biology
Evangelos Terpos et al.
Summary: The study revealed a persistent but declining humoral immunity against SARS-CoV-2 at six months following full vaccination with BNT162b2 in healthy individuals, with older individuals showing more pronounced decline. About half of the subjects are estimated to have Nabs values below 73.8% and 64.6% at 9 and 12 months post vaccination completion, respectively.
Letter
Medicine, General & Internal
Nicole Doria-Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medical Laboratory Technology
Andrea Padoan et al.
Summary: The study found significant differences in antibody levels at day 12 after receiving the BNT162b2 vaccine between infection-naive individuals and those with previous natural infection, but no differences were observed thereafter. There were no statistically significant differences between males and females, while individuals over 60 years of age had lower antibody levels at day 12 but not at day 28. The influence of sex and age on vaccine responses warrants further investigation, with age showing particular significance.
CLINICA CHIMICA ACTA
(2021)
Review
Biochemical Research Methods
Aria C. Shi et al.
Summary: The COVID-19 pandemic has had a devastating impact on society and economy, with the development of an effective vaccine and establishment of herd immunity being key to ending the pandemic. Reliable serology testing is crucial for diagnosing infections and monitoring neutralizing antibody levels, but there are still challenges in the development and application of these tests.
JOURNAL OF IMMUNOLOGICAL METHODS
(2021)
Letter
Infectious Diseases
Gian Luca Salvagno et al.
JOURNAL OF INFECTION
(2021)
Review
Immunology
Yuying Lu et al.
Summary: The COVID-19 pandemic has caused a global health emergency with tremendous efforts put into controlling it. Neutralizing antibodies are of interest to researchers for their ability to protect cells and potentially be used in vaccines and patient treatment. Various neutralization assays are being developed to quantify these antibodies and explore their relationship with disease severity and potential for reinfection in patients.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2021)
Article
Cell Biology
Andrzej Tretyn et al.
Summary: The study evaluated the antibody levels against SARS-CoV-2 virus and cellular immune response after the vaccination with mRNA vaccines. High levels of antibodies were observed in 98% of the vaccinated cohort, and all participants had protective T cells. The immune response is diversified, visible as early as 2-3 weeks after the first dose, and the level of protection significantly increased after the second dose, especially in pre-vaccine healthy subjects.
Article
Health Care Sciences & Services
Paul Naaber et al.
Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Medicine, General & Internal
E. J. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Medicine, General & Internal
Andrea Padoan et al.
